

*CHESSMEN*

*“Coordination and Harmonisation of  
the Existing Systems against  
Shortages of Medicines – European  
Network”*

11/03/2025


# About CHESSMEN

CHESSMEN (Coordination and Harmonisation of the Existing Systems against Shortages of Medicines – European Network) is a co-funded Joint Action that envisages to support European Member States to provide a harmonized response to medicinal products shortages and promote the use of best preventive practices.

The Joint Action has officially started on 16 January 2023 and will be running for 3 years, bringing together 22 countries. The Italian Medicines Agency (AIFA, Agenzia Italiana del Farmaco), supported by the Italian National Blood and Transplant Centers (ISS-CNS/CNT), is responsible for the coordination of the Joint Action.



Starting date  
**16/01/2023**



**3** years



**7,85 million €** co-  
funding by EC



**21** EU Member States  
and **1** EEA country




**22** Beneficiaries


**5** Affiliated Entities

# Coordinator

**AIFA** - Agenzia Italiana del Farmaco (Italian Medicines Agency), supported by the Italian National Blood and Transplant Centres (ISS-CNS/CNT)



# Beneficiaries



**AIFA** – Agenzia Italiana del Farmaco (Italy)

**AEMPS** - Agencia Espanola De Medicamentos Y Productos Sanitarios (Spain)

**ANSM** - The Agence Nationale de Sécurité du Médicament et des Produits de Santé (France)

**ATNA** - The Austrian Ministry of Social Affairs, Health, Care and Consumer Protection (Austria)

**BFARM** - Bundesinstitut Für Arzneimittel Und Medizinprodukte (Germany)

**DKMA** - The Danish Medicines Agency (Denmark)

**DPM** - The Division of Pharmacy and Medicines within the Luxembourg Health Directorate (Luxembourg)

**ESSC** – Health Emergency Situation Centre of The Ministry of Health of Lithuania (Lithuania)

**FAMHP**- Federal Agency for Medicines and Health Products (Belgium)

**FIMEA** - Lääkealan Turvallisuus- Ja Kehittämiskeskus (Finland)

**HALMED** - Agencija za Lijekove I Medicinske Proizvode (Croatia)

**HPRA** - The Health Products Regulatory Authority (Ireland)

**INFARMED** – The Autoridade Nacional Do Medicamento E Produtos De Saúde I.p. (Portugal)

**JAZMP** - Javna Agencija Republike Slovenije Za Zdravila in Medicinske Pripomočke / Agency for Medicinal Products and Medical Devices of The Republic Of Slovenia (Slovenia)

**LÄKEMEDELSVERKET** - The Swedish Medicinal Products Agency (Sweden)

**MINISTRY VWS** - The Department of Pharmaceutical Affairs and Medical Technology of The Dutch Ministry of Health, Welfare and Sport (Netherlands)

**MS/MOH** - Ministerul Sănătății România (Romania)

**NoMA** - Statens Legemiddelverk (Norway)

**OGYEI** - Országos Gyógyszerészeti És Élelmezés-egészségügyi Intézet (Hungary)

**PHS** - The Pharmaceutical Services of Cyprus (Cyprus)

**SAM** - Estonian State Agency of Medicines (Estonia)

**SUKL** - Státní Ústav Pro Kontrolu Léčiv (Czech Republic)

# Affiliated Entities



**AGES/BASG** - Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH (Austria)

**GÖG** - Gesundheit Österreich GmbH (Austria)

**ISS – CNS/CNT** – Istituto Superiore Di Sanità, Centro Nazionale Sangue, Centro Nazionale Trapianti (Italy)

**NAMMDR** - Agentia Nationala a Medicamentului Si a Dispozitivelor Medicale din Romania (Romania)

**PEI** - Paul Ehrlich Institut (Germany)

# Work-Packages (WPs) Objectives

## Horizontal Work-Packages

- **WP 1**  
**Coordination and management**  
Leader AIFA, Italy
- **WP 2**  
**Communication, dissemination and exploitation**  
Leader INFARMED, I.P., Portugal
- **WP 3**  
**Evaluation**  
Leader FAMHP, Belgium
- **WP 4**  
**Sustainability**  
Leader HPRA, Ireland

## Technical Work-Packages

- **WP 5**  
**Identifying the root causes of observed shortages of medicines**  
Leader AEMPS, Spain
- **WP 6**  
**Identification of best practices to address medicines shortages**  
Leader JAZMP, Slovenia
- **WP 7**  
**Digital information exchange for monitoring and reporting medicine shortages**  
Leader BfArM, Germany
- **WP 8**  
**Reducing the likelihood of medicines shortage via preventive and mitigation strategies**  
Leader FIMEA, Finland

# WP 5 - Identifying the root causes of observed shortages of medicines



## **D 5.2: Review on Existing Documents or Information Relating to Root Causes of Medicine Shortages in the EU**

### **Dissemination level: Sensitive**

A comprehensive review of existing documents and information related to the root causes of medicine shortages in EU Member States, supported by surveys to both partners of the Consortium and external target groups to address information gaps.



## **D 5.3: Analysis Report on Root Causes**

### **Dissemination level: Public**

Based on the work developed on D 5.1 and D 5.2, a report will be elaborated on the analysis and categorization of root causes of medicine shortages.

# WP 6 - Identification of best practices to address medicines shortages

## ✓ **D 6.1: Report on the Existing Documents on Shortages of Medicines**

### **Dissemination level: Sensitive**

A report of collected existing documents, such as guidelines, legislation, and reports from MSS and key organizations, with consortium partners sharing best practices, relevant documents, and demand forecasting experiences.

## **D6.2 – Final Report on the common protocol for monitoring and reporting of shortages**

### **Dissemination level: Public**

Following an initial mapping activity, the WP will elaborate a common protocol for monitoring, reporting and managing. This excludes IT systems and prevention strategies.

## **D6.3 – Final Report on the EU Article 6.1 list at the level of active substances and medicinal products**

### **Dissemination level: Public**

The WP will populate a list of therapeutic groups need for emergency, surgical and intensive care. This activity also includes a pilot availability exercise.



# WP 6 - Identification of best practices to address medicines shortages

## **D6.4 – Recommendations for development of National lists of critical medicines**

### **Dissemination level: Public**

Following the work done in the previous deliverables, the WP will work on the establishment of recommendations for increased harmonization within National lists of critical medicines.

## **D6.5 – Training workshop on WP6 outputs**

### **Dissemination level: Public**

Preparation of a target workshop for the dissemination and transfer of knowledge resulting from the work developed in WP6.

# WP 7 - Digital information exchange for monitoring and reporting medicine shortages

## ✓ D 7.1: Analysis Report on the IT Solutions at EU and MS

### **Dissemination level: Sensitive**

An analysis of existing IT solutions at both EU and MS level for shortage notification and monitoring, identifying strengths, weaknesses, opportunities, threats, and country-specific data sources beyond national Competent Authorities.

## ✓ D 7.2: Report on EU Best Practice Solutions and Minimum Common Datasets

### **Dissemination level: Public**

A proposal of best practice solutions and minimum common datasets to harmonize data collection and support the elaboration of an operating concept platform.

## **D7.3 – Concept platform to monitor and manage medicines shortages**

### **Dissemination level: Public**

Development of an implementation concept for a platform addressed to MAH, EMA, and wholesalers, while also providing information to other stakeholders as physicians, hospitals and pharmacists in reusing existing data.

# WP 8 - Reducing the likelihood of medicines shortage via preventive and mitigation strategies

## **D8.1 – Analysis Report on of the existing preventive and mitigation at national level**

### **Dissemination level: Sensitive**

Collection and mapping of documentation related to the prevention and mitigation measures in the different MS. Analysis and establishment of the methodological approach used in the selection of the measures (inclusion and exclusion criteria).

## **D8.2 – Prevention and Mitigation Plan**

### **Dissemination level: Public**

Development of a plan specifically defining best practice proposals relating to preventive and mitigation measures to tackle medicine shortages.

# WP 8 - Reducing the likelihood of medicines shortage via preventive and mitigation strategies

## **D8.3 – Implementation plan**

### **Dissemination level: Public**

Development of an implementation plan addressed to national CA with recommendations to harmonise the approaches taken at a national level.

## **D8.4 – Position Paper**


### **Dissemination level: Public**

Development of European recommendation for minimum standards in order to support increased harmonization/transparency of the existing data, and support timely communication of information.

# Dissemination Channels


# Website

<https://www.ja-chessmen.eu/>



# LinkedIn

<https://www.linkedin.com/company/jachessmen/>



*Thank you!*

*Grant Agreement 101082419 – EU4H-2021-JA2-IBA*

*January 2023 – January 2026*

*This presentation is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.*